Spero Therapeutic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Spero therapeutic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Spero Therapeutic Today - Breaking & Trending Today

Head to Head Survey: Coya Therapeutics (NASDAQ:COYA) vs. Spero Therapeutics (NASDAQ:SPRO)

Coya Therapeutics (NASDAQ:COYA – Get Free Report) and Spero Therapeutics (NASDAQ:SPRO – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership. Volatility and Risk Coya Therapeutics has a […] ....

United Kingdom , United States , South Korea , Vertex Pharmaceuticals Incorporated , Spero Therapeutics Inc , Coya Therapeutics Inc , Meiji Seika Pharma Co Ltd , Melinda Gates Medical Research Institute , Coya Therapeutics , Get Free Report , Spero Therapeutics , Spero Therapeutic , Given Spero Therapeutic , Amyotrophic Lateral , Frontotemporal Dementia , Everest Medicines , Southeast Asian , Coya Therapeutics Daily , Nasdaq Coya , Stock Comparison , Stock Analysis ,

Spero Therapeutics, Inc. (NASDAQ:SPRO): Are Analysts Optimistic?

We feel now is a pretty good time to analyse Spero Therapeutics, Inc.'s ( NASDAQ:SPRO ) business as it appears the. ....

Management Team , Spero Therapeutic , Spero Therapeutics , Simply Wall , High Performing Stocks , Biopharmaceutical Company , Breakeven Point ,

Cantor Fitzgerald Reaffirms Overweight Rating for Spero Therapeutics (NASDAQ:SPRO)

Cantor Fitzgerald reissued their overweight rating on shares of Spero Therapeutics (NASDAQ:SPRO – Free Report) in a report published on Monday morning, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Spero Therapeutics’ FY2024 earnings at ($0.85) EPS. Separately, HC Wainwright restated a buy rating and set a $7.00 price objective on shares of Spero Therapeutics […] ....

United States , Blackrock Inc , Cantor Fitzgerald , Spero Therapeutics Company Profile , Renaissance Technologies , Spero Therapeutics Inc , Millennium Management , Vanguard Group Inc , Spero Therapeutics , Free Report , Spero Therapeutic , Therapeutics Stock Down , Get Free Report , Funds Management , Spero Therapeutics Daily , Nasdaq Spro , Reiterated Rating ,

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q3 2023 Earnings Call Transcript

Ted Jenkins: Thank you, operator, and thank you all for participating in today s conference call. ....

United States , Kevin Winthrop , Sath Shukla , Patrick Vink , Milind Deshpande , Ted Jenkins , Steve Dipalma , Esther Rajavelu , Boobalan Pachaiyappan , Ankit Mahadevia , Kamal Hamed , Louise Chen , Science University , Smartpros Ltd , Xavier Life Tech Corporation , Spero Therapeutics Inc , Oregon Health , Cantor Fitzgerald , Spero Therapeutics , Call Transcript November , Spero Therapeutic , Chief Executive Officer , Chief Medical Officer , Chief Financial Officer , Chief Business , Special Protocol Assessment ,

What's in Store for Boston Scientific (BSX) in Q3 Earnings?

With global staffing issues and the supply situation gradually improving, Boston Scientific's (BSX) international business is expected to have improved further in the third quarter. ....

United States , Asia Pacific , Apollo Endosurgery , Wavewriter Alpha , Prostate Health , Zacks Investment Research , Access Solutions , Boston Scientific , Pelvic Health , Ligand Pharmaceuticals , Urology Pelvic Health , Boston Scientific Corporation , World Medical Device , Interventional Cardiology , Coronary Therapie , Heart Valves , Peripheral Interventions , Packing Coils , Spinal Cord Stimulation , Vercise Genus , Zacks Consensus Estimate , Zacks Rank , Strong Buy , Ligand Pharmaceutical , Spero Therapeutic , Inspire Medical ,